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S1, a new chromogenic cephalosporin (International BioClinical, Inc., Portland, Oreg.), was used to detect
b-lactamase production among a variety of commonly encountered bacteria in a four-center collaborative
study. Results of an S1 disk assay were compared with those obtained by a nitrocefin-based disk procedure
(Cefinase; Becton-Dickinson Microbiology Systems, Cockeysville, Md.), with repetitive testing of five quality
control organisms and with individual tests of recent clinical isolates of Neisseria gonorrhoeae (162 strains),
Haemophilus influenzae (162 strains), Moraxella catarrhalis (155 strains), Staphylococcus aureus (161 strains),
and Bacteroides fragilis (164 strains). The performances of the two b-lactamase disk assays were comparable
for the first three species cited above. However, the S1 assay appeared to be a more sensitive procedure than
the Cefinase assay when applied to S. aureus and B. fragilis, with respect to both total numbers of positive
results and length of time to a definitive positive endpoint.
Determination of b-lactamase production in the clinical mi-
crobiology laboratory has served as a useful means for predict-
ing the activity of the penicillins against certain bacteria, in
particular Haemophilus influenzae, Neisseria gonorrhoeae,
Moraxella catarrhalis, and Staphylococcus aureus (16, 19, 23). A
variety of b-lactamase detection techniques have been devel-
oped, including acidometric (2, 6, 10, 18, 20, 22, 24), iodomet-
ric (4, 12, 21), and chromogenic cephalosporin-based assays.
Among the last, at least three reagents have been described:
PADAC (1, 3, 8, 11), CENTA (9), and nitrocefin (13, 17), the
last of which has become most commonly utilized. Reasons for
the popularity of this test system are its commercial availability
(e.g., Cefinase disks [Becton-Dickinson Microbiology Systems,
Cockeysville, Md.] and Dry-Slide [Difco, Inc., Detroit, Mich.]),
logistical simplicity, availability of results within seconds to
minutes, reliability, and the fact that the nitrocefin disk test has
proven to be the only accurate means for detecting b-lacta-
mase production by M. catarrhalis. False-negative results are
often obtained for this bacterium when tested with acidimetric
or iodometric assays or procedures based on the other chro-
mogenic cephalosporins (5, 7). Unfortunately, even nitrocefin-
based b-lactamase assays have not proven useful in detecting
b-lactamase production by organisms in the Bacteroides fragilis
group, organisms commonly found to be penicillin resistant by
virtue of production of a b-lactamase. For this reason, devel-
opment of new, chromogenic cephalosporin b-lactamase re-
agents is highly desirable.
Recently, Sutton and colleagues described a novel chromo-
genic cephalosporin, called S1 or cefesone (23). This com-
pound, 3-(2,4-dinitrostyryl)-(6R,7R)-7-phenylacetamido-ceph-
3-em-4-carboxylate, has been shown in a single-center study to
be a potentially useful substrate for detecting b-lactamase pro-
duction among a variety of commonly encountered bacteria.
The intent of the current study was to systematically evaluate
a disk assay for b-lactamase production based on the S1 chro-
mogenic substrate (International BioClinical, Inc., Portland,
Oreg.) in four clinical microbiology laboratories using recent
isolates of H. influenzae, Streptococcus pneumoniae, M. ca-
tarrhalis, S. aureus, and the B. fragilis group. S1 b-lactamase
results were compared with those obtained with the Cefinase
disk procedure.
Each of the four participating laboratories examined ca. 40
recent clinical isolates of each of the following organisms: N.
gonorrhoeae, H. influenzae, M. catarrhalis, S. aureus, and the B.
fragilis group. Colonies (16 to 24 h) on enriched chocolate agar
(i.e., N. gonorrhoeae and H. influenzae), 5% sheep blood agar
(i.e., M. catarrhalis and S. aureus), or supplemented brucella
anaerobic agar plus 5% sheep blood (i.e., B. fragilis) were used
for b-lactamase assays. On each day of testing, the following
five quality control strains were also each examined once:
Escherichia coliATCC 35218, B. fragilisATCC 25285, S. aureus
ATCC 29213, H. influenzae ATCC 10211, and S. aureus ATCC
25923. The expected b-lactamase assay results for these con-
trol organisms were positive, positive, positive, negative, and
negative, respectively.
A nitrocefin b-lactamase assay using Cefinase disks was per-
formed explicitly according to the manufacturer’s instructions.
Briefly, 6-mm-diameter filter paper disks impregnated with
nitrocefin were moistened with 0.85% NaCl, and several well-
isolated colonies of test organisms were transferred to the disk
with a wooden applicator stick or wire loop. The investiga-
tional b-lactamase assay using disks impregnated with the S1
chromogenic cephalosporin was performed in exactly the same
manner. Disks were examined for the appearance of a pink-red
coloration for up to 60 min with isolates of S. aureus, up to 30
min with B. fragilis group isolates, and up to 10 min with the
other three species. The length of time to the appearance of a
definitive positive reaction was noted.
Methicillin MICs for selected isolates of staphylococci were
determined by using a broth microdilution method as de-
scribed by the National Committee for Clinical Laboratory
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Standards (15). The ampicillin-sulbactam (2:1) and penicillin
MICs for selected B. fragilis group isolates were determined by
using a microdilution procedure in brain heart infusion broth
as described by the National Committee for Clinical Labora-
tory Standards (14).
Intra- and interlaboratory reproducibility was assessed by
repetitive testing of the five quality control strains noted above.
Each quality control strain was tested 21 times: 5 times in
laboratory A, 8 times in laboratory B, 3 times in laboratory C,
and 5 times in laboratory D. Complete concordance between
the results of the S1 and Cefinase b-lactamase assays was
observed with four of the five quality control strains. Only B.
fragilis ATCC 25285 yielded discordant results, with 10 of 21
determinations falsely negative by the nitrocefin assay. Among
these 10 discrepancies, 4 were obtained in laboratory A, 1 was
obtained in laboratory C, and 5 were obtained in laboratory D.
The mean lengths of time to positive results with E. coli ATCC
35218 and S. aureus ATCC 29213 varied between 1.4 and 1.8
min within each assay. With B. fragilis ATCC 25285, positive
results were obtained with each assay at 3.6 to 4.2 min.
As noted in Table 1, exact concordance between the results
of the S1 and Cefinase b-lactamase assays was observed for
clinical isolates of N. gonorrhoeae (162 isolates), H. influenzae
(162 isolates), M. catarrhalis (155 isolates), and all but 2 of 161
isolates of S. aureus. The two discordant results obtained with
S. aureus were both from laboratory A and appeared to be
false-negative Cefinase test results, since the MICs of penicillin
for both isolates, following induction with 0.05 mg of methicil-
lin per ml, were found to be .1.0 mg/ml.
The overall mean lengths of time to a definitive positive test
result were very similar with the two assays forH. influenzae, N.
gonorrhoeae, and M. catarrhalis, i.e., 36 to 48 s. With clinical
isolates of S. aureus, the overall mean lengths of time to a
positive test result were consistently longer with both b-lacta-
mase assays (i.e., 7.0 min with the S1 assay and 10.6 min with
the Cefinase test). The S1 assay, however, clearly yielded de-
finitive positive results more quickly than the Cefinase proce-
dure. For S. aureus, in general, laboratories A and C were
similar with respect to mean lengths of time to a positive test
result and faster than laboratories B and D which, in turn, were
comparable.
The results of tests with clinical isolates of B. fragilis are
depicted in Table 2. Because conspicuous interlaboratory vari-
ability was noted with this organism group, results are indexed
by individual laboratory. On the assumption that the large
majority of B. fragilis isolates produced b-lactamase, large
numbers of apparent false-negative results were obtained with
the Cefinase assay in laboratories A and D. In laboratory B,
both b-lactamase assays yielded numerous false-negative re-
sults. Only in laboratory C were most isolates of B. fragilis (i.e.,
39 of 41) found to be positive with both the S1 and the Cefinase
assays. The mean lengths of time to a strong positive test result
also varied among laboratories (i.e., 3.5 to 8.0 min with the S1
assay and 3.7 to 5.8 min with the Cefinase procedure). In
general, however, positive S1 results were observed 1 to 2 min
sooner than were positive results with the Cefinase procedure.
In an attempt to clarify the apparent interlaboratory vari-
ability noted with the two b-lactamase assays for isolates of the
B. fragilis group, 10 isolates were obtained from each of the
four study centers and examined in a single laboratory (labo-
ratory A). The MICs of ampicillin-sulbactam and penicillin
were determined, and both b-lactamase assays were repeated.
Thirty-one of these 40 isolates were judged as clearly produc-
ing b-lactamase on the basis of the disparity between ampicil-
lin-sulbactam MICs (#1.0 mg/ml) and penicillin MICs ($16
mg/ml). All 31 isolates yielded positive results with the S1
assay; 20 (64.5%) were positive with the Cefinase procedure.
Six of the 40 B. fragilis group isolates appeared to be b-lacta-
mase negative, since the MICs of penicillin for these isolates
were #4.0 mg/ml. One of these six isolates produced weakly
positive results after 30 min with the S1 assay; all were negative
with the Cefinase disk procedure. The one isolate which
yielded an apparent weakly positive S1 result was negative
upon retesting. Interestingly, the MICs of penicillin and am-
picillin-sulbactam for the remaining three isolates in this col-
lection of 40 B. fragilis group organisms were high ($32 mg/
ml). All three isolates were positive with the S1 assay; two of
the three were Cefinase positive.
S1, a novel new chromogenic cephalosporin, proved to be an
effective substrate for detection of b-lactamase production by
several commonly encountered bacteria when tested in a disk
assay format. Comparison of results obtained by the S1 disk
assay with those obtained by the Cefinase disk procedure re-
vealed complete agreement for numerous clinical isolates ofH.
influenzae, N. gonorrhoeae, and M. catarrhalis in terms of num-
bers of positive and negative results and length of time to a
positive test result. The results obtained with the S1 reagent
with M. catarrhalis are particularly important, as nitrocefin has
heretofore been the only effective reagent for detecting b-lac-
tamase production by this organism (5, 7).
TABLE 1. Concordance of results of S1 and Cefinase disk
b-lactamase assays applied to clinical isolates of









N. gonorrhoeae (162) Positive 72 0
Negative 0 90
H. influenzae (162) Positive 79 0
Negative 0 83
M. catarrhalis (155) Positive 129 0
Negative 0 26
S. aureus (161) Positive 128 2c
Negative 0 31
a Combined results of all four laboratories.
b The numbers of clinical isolates of each of the study organisms were as
follows for laboratories A through D: N. gonorrhoeae, 40, 42, 40, and 40, respec-
tively; H. influenzae, 40, 42, 40, and 40, respectively;M. catarrhalis, 40, 34, 41, and
40, respectively; and S. aureus, 40, 41, 40, and 40, respectively.
c Additional results obtained with these two isolates of S. aureus are described
in the text.
TABLE 2. Concordance of results of S1 and Cefinase disk
b-lactamase assays with clinical isolates of B. fragilis
in four laboratories
Laboratory S1 b-lactamasetest result




A Positive 13 23
Negative 0 4
B Positive 6 0
Negative 0 37
C Positive 39 0
Negative 0 2
D Positive 11 26
Negative 0 3
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With clinical isolates of S. aureus, the S1 disk test was found
to be slightly more sensitive than the nitrocefin procedure,
both in terms of total numbers of true-positive test results and
in terms of length of time to a definitive positive test result.
Enhanced sensitivity of the S1 assay was even more conspicu-
ous with the B. fragilis group, for which, among a total of 164
clinical isolates, 49 (29.9%) were positive in the S1 assay but
negative with the nitrocefin procedure. Furthermore, when
comparisons were restricted to isolates that were positive by
both assays, the length of time to a positive test result was
consistently shorter with the S1 assay (mean, 2.3 min faster).
The results obtained with B. fragilis group isolates deserve
further mention. In terms of percentages of strains found to
yield specific patterns of reactivity with the two assays, labora-
tories fell into one of three groups. Laboratory C found 39 of
41 strains (95.1%) to be positive with both assays; 2 of 41
strains were negative by both procedures. By contrast, labora-
tories A and D both found roughly two-thirds of test strains to
yield apparent true-positive results with the S1 assay but false-
negative results with Cefinase disks, i.e., 23 of 40 strains
(57.5%) in laboratory A and 26 of 40 strains (65.0%) in labo-
ratory D. These discordant results were judged as representing
false-negative nitrocefin findings at least in laboratory A, since
for the 23 isolates in this laboratory with positive S1 but neg-
ative nitrocefin results, in all cases, the penicillin MIC was
noted to be .8 mg/ml on the basis of a broth microdilution
procedure which used supplemented brain heart infusion broth
as a growth medium. Laboratory B, on the other hand, ob-
served absolute concordance between the two assays with B.
fragilis isolates; however, 37 of 43 strains (86.0%) yielded un-
expected negative results with both assays. It is presumed that
these represented false-negative results, since the vast majority
of B. fragilis group isolates would be expected to be resistant to
penicillin because of production of b-lactamase. Penicillin
MICs were not available for the test isolates of B. fragilis in
laboratory B.
There is no obvious explanation for the interlaboratory vari-
ation observed with the nitrocefin disk test with B. fragilis or
the conspicuously lower sensitivity observed in laboratory B
with the S1 procedure for this organism group. However,
among the four participating laboratories, lengths of time to a
positive test result were generally longest in laboratory B for all
five organism groups. This was perhaps due to observer bias,
i.e., higher thresholds for calling results positive, or possible
use of smaller inocula for b-lactamase tests in laboratory B.
The results obtained with the control organisms seem to sup-
port the former assumption (data not given).
In conclusion, use of the S1 chromogenic cephalosporin in a
disk assay was found to be at least comparable to the Cefinase
disk procedure as a means of detecting b-lactamase production
by N. gonorrhoeae, H. influenzae, and M. catarrhalis. The S1
assay was superior for identifying b-lactamase-producing iso-
lates of S. aureus. Results obtained with B. fragilis were variable
and require further study; however, the S1 reagent may pro-
vide the first useful means for detecting b-lactamase activity
with this organism group as well.
We thank Debbie McQuaid for excellent secretarial assistance.
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